JP2020503351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503351A5 JP2020503351A5 JP2019536179A JP2019536179A JP2020503351A5 JP 2020503351 A5 JP2020503351 A5 JP 2020503351A5 JP 2019536179 A JP2019536179 A JP 2019536179A JP 2019536179 A JP2019536179 A JP 2019536179A JP 2020503351 A5 JP2020503351 A5 JP 2020503351A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- til
- oxazole
- cell culture
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 57
- 239000006143 cell culture medium Substances 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 229940122117 Potassium channel agonist Drugs 0.000 claims 12
- 239000000556 agonist Substances 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 108010002350 Interleukin-2 Proteins 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 7
- 239000000651 prodrug Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 239000013078 crystal Substances 0.000 claims 6
- -1 cyano, hydroxy Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 230000012010 growth Effects 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 230000035755 proliferation Effects 0.000 claims 5
- PJCGPTKFLDZUQC-UHFFFAOYSA-N 1,3-oxazole-2,5-diamine Chemical compound NC1=CN=C(N)O1 PJCGPTKFLDZUQC-UHFFFAOYSA-N 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102100027207 CD27 antigen Human genes 0.000 claims 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 108091006146 Channels Proteins 0.000 claims 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 150000003573 thiols Chemical class 0.000 claims 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 2
- 108090000172 Interleukin-15 Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- FECQXVPRUCCUIL-UHFFFAOYSA-N benzo[e][1,3]benzothiazol-2-amine Chemical group C1=CC=C2C(N=C(S3)N)=C3C=CC2=C1 FECQXVPRUCCUIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000106 biosimilars Drugs 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000007789 gas Substances 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 239000002609 medium Substances 0.000 claims 2
- YKXKYTRQOWDNGL-UHFFFAOYSA-N naphtho[2,3-g][1,3]benzothiazol-2-amine Chemical group C1=CC=CC2=CC3=C(SC(N)=N4)C4=CC=C3C=C21 YKXKYTRQOWDNGL-UHFFFAOYSA-N 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- VDBHXYJASQFWIO-UHFFFAOYSA-N 2-aminobenzo[e][1,3]benzoxazole-5-carbonitrile Chemical compound NC=1OC2=C(N=1)C1=CC=CC=C1C(=C2)C#N VDBHXYJASQFWIO-UHFFFAOYSA-N 0.000 claims 1
- UELLPMFGNHXKLA-UHFFFAOYSA-N 2-aminobenzo[g][1,3]benzoxazole-5-carbonitrile Chemical compound NC=1OC2=C(N=1)C=C(C1=CC=CC=C12)C#N UELLPMFGNHXKLA-UHFFFAOYSA-N 0.000 claims 1
- QDDGBSMVRRPBNO-UHFFFAOYSA-N 5-(trifluoromethyl)benzo[e][1,3]benzoxazol-2-amine Chemical compound FC(C1=CC2=C(N=C(O2)N)C2=CC=CC=C12)(F)F QDDGBSMVRRPBNO-UHFFFAOYSA-N 0.000 claims 1
- FGNDODOSBITQQS-UHFFFAOYSA-N 5-N,5-N-dimethylbenzo[g][1,3]benzoxazole-2,5-diamine Chemical compound CN(C1=CC=2N=C(OC=2C2=CC=CC=C12)N)C FGNDODOSBITQQS-UHFFFAOYSA-N 0.000 claims 1
- LPQKGQSTONLLEF-UHFFFAOYSA-N 5-N-methylbenzo[g][1,3]benzoxazole-2,5-diamine Chemical compound CNC1=CC=2N=C(OC=2C2=CC=CC=C12)N LPQKGQSTONLLEF-UHFFFAOYSA-N 0.000 claims 1
- XQZQRMWACQFKDE-UHFFFAOYSA-N 5-bromobenzo[g][1,3]benzoxazol-2-amine Chemical compound BrC1=CC=2N=C(OC=2C2=CC=CC=C12)N XQZQRMWACQFKDE-UHFFFAOYSA-N 0.000 claims 1
- XNKGZAZVMMEVOF-UHFFFAOYSA-N 5-chlorobenzo[e][1,3]benzoxazol-2-amine Chemical compound ClC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 XNKGZAZVMMEVOF-UHFFFAOYSA-N 0.000 claims 1
- PBBGASLTRVOMQL-UHFFFAOYSA-N 5-chlorobenzo[g][1,3]benzoxazol-2-amine Chemical compound ClC1=CC=2N=C(OC=2C2=CC=CC=C12)N PBBGASLTRVOMQL-UHFFFAOYSA-N 0.000 claims 1
- FYWXMVHQWUJYDS-UHFFFAOYSA-N 5-cyclopropylbenzo[e][1,3]benzoxazol-2-amine Chemical compound C1(CC1)C1=CC2=C(N=C(O2)N)C2=CC=CC=C12 FYWXMVHQWUJYDS-UHFFFAOYSA-N 0.000 claims 1
- BQVBELYILSDYNP-UHFFFAOYSA-N 5-cyclopropylbenzo[g][1,3]benzoxazol-2-amine Chemical compound C1(CC1)C1=CC=2N=C(OC=2C2=CC=CC=C12)N BQVBELYILSDYNP-UHFFFAOYSA-N 0.000 claims 1
- MCELLMQOWOJPNT-UHFFFAOYSA-N 5-ethylbenzo[e][1,3]benzoxazol-2-amine Chemical compound C(C)C1=CC2=C(N=C(O2)N)C2=CC=CC=C12 MCELLMQOWOJPNT-UHFFFAOYSA-N 0.000 claims 1
- XSMNCNBWZGMLQB-UHFFFAOYSA-N 5-ethylbenzo[g][1,3]benzoxazol-2-amine Chemical compound C(C)C1=CC=2N=C(OC=2C2=CC=CC=C12)N XSMNCNBWZGMLQB-UHFFFAOYSA-N 0.000 claims 1
- SNZBYSFJIDWLSV-UHFFFAOYSA-N 5-fluorobenzo[e][1,3]benzoxazol-2-amine Chemical compound FC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 SNZBYSFJIDWLSV-UHFFFAOYSA-N 0.000 claims 1
- ZLSFZVIIFYRZHT-UHFFFAOYSA-N 5-fluorobenzo[g][1,3]benzoxazol-2-amine Chemical compound FC1=CC=2N=C(OC=2C2=CC=CC=C12)N ZLSFZVIIFYRZHT-UHFFFAOYSA-N 0.000 claims 1
- HDLVZWLBHNDJKG-UHFFFAOYSA-N 5-iodobenzo[e][1,3]benzoxazol-2-amine Chemical compound IC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 HDLVZWLBHNDJKG-UHFFFAOYSA-N 0.000 claims 1
- VPIVAGJDHNUEBU-UHFFFAOYSA-N 5-iodobenzo[g][1,3]benzoxazol-2-amine Chemical compound IC1=CC=2N=C(OC=2C2=CC=CC=C12)N VPIVAGJDHNUEBU-UHFFFAOYSA-N 0.000 claims 1
- LJMNLIBLKUDURS-UHFFFAOYSA-N 5-methoxybenzo[g][1,3]benzoxazol-2-amine Chemical compound COC1=CC=2N=C(OC=2C2=CC=CC=C12)N LJMNLIBLKUDURS-UHFFFAOYSA-N 0.000 claims 1
- JEGUERWMMMQFJV-UHFFFAOYSA-N 5-methylbenzo[g][1,3]benzoxazol-2-amine Chemical compound C12=CC=CC=C2C(C)=CC2=C1OC(N)=N2 JEGUERWMMMQFJV-UHFFFAOYSA-N 0.000 claims 1
- HYACVPUCNYACMP-UHFFFAOYSA-N 5-propylbenzo[e][1,3]benzoxazol-2-amine Chemical compound C(CC)C1=CC2=C(N=C(O2)N)C2=CC=CC=C12 HYACVPUCNYACMP-UHFFFAOYSA-N 0.000 claims 1
- UBXLSSOXYRRGTH-UHFFFAOYSA-N 5-pyrrolidin-1-ylbenzo[e][1,3]benzoxazol-2-amine Chemical compound N1(CCCC1)C1=CC2=C(N=C(O2)N)C2=CC=CC=C12 UBXLSSOXYRRGTH-UHFFFAOYSA-N 0.000 claims 1
- WLDWRKQIARYAHZ-UHFFFAOYSA-N 5-pyrrolidin-1-ylbenzo[g][1,3]benzoxazol-2-amine Chemical compound N1(CCCC1)C1=CC=2N=C(OC=2C2=CC=CC=C12)N WLDWRKQIARYAHZ-UHFFFAOYSA-N 0.000 claims 1
- ONWLBSYAHSDYHU-UHFFFAOYSA-N 5-tert-butylbenzo[e][1,3]benzoxazol-2-amine Chemical compound C(C)(C)(C)C1=CC2=C(N=C(O2)N)C2=CC=CC=C12 ONWLBSYAHSDYHU-UHFFFAOYSA-N 0.000 claims 1
- WPLUMABBTJAHNC-UHFFFAOYSA-N 5-tert-butylbenzo[g][1,3]benzoxazol-2-amine Chemical compound C(C)(C)(C)C1=CC=2N=C(OC=2C2=CC=CC=C12)N WPLUMABBTJAHNC-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- HPENHUHDYSJQCG-UHFFFAOYSA-N BrC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 Chemical compound BrC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 HPENHUHDYSJQCG-UHFFFAOYSA-N 0.000 claims 1
- WUGYLKBNAMMWOP-UHFFFAOYSA-N C(CC)C1=CC=2N=C(OC2C2=CC=CC=C12)N Chemical compound C(CC)C1=CC=2N=C(OC2C2=CC=CC=C12)N WUGYLKBNAMMWOP-UHFFFAOYSA-N 0.000 claims 1
- ZRJSCBAHHYQKLX-UHFFFAOYSA-N CC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 Chemical group CC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 ZRJSCBAHHYQKLX-UHFFFAOYSA-N 0.000 claims 1
- HRQMEFOFGGEYMS-UHFFFAOYSA-N COC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 Chemical compound COC1=CC2=C(N=C(O2)N)C2=CC=CC=C12 HRQMEFOFGGEYMS-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 102100038595 Estrogen receptor Human genes 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102100025803 Progesterone receptor Human genes 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical group C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 108700025316 aldesleukin Proteins 0.000 claims 1
- 229960005310 aldesleukin Drugs 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 230000008472 epithelial growth Effects 0.000 claims 1
- 108010038795 estrogen receptors Proteins 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000001400 myeloablative effect Effects 0.000 claims 1
- 108090000468 progesterone receptors Proteins 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022180592A JP7682840B2 (ja) | 2017-01-06 | 2022-11-10 | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443519P | 2017-01-06 | 2017-01-06 | |
| US62/443,519 | 2017-01-06 | ||
| US201762466921P | 2017-03-03 | 2017-03-03 | |
| US62/466,921 | 2017-03-03 | ||
| US201762504385P | 2017-05-10 | 2017-05-10 | |
| US62/504,385 | 2017-05-10 | ||
| PCT/US2018/012610 WO2018129336A1 (en) | 2017-01-06 | 2018-01-05 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022180592A Division JP7682840B2 (ja) | 2017-01-06 | 2022-11-10 | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503351A JP2020503351A (ja) | 2020-01-30 |
| JP2020503351A5 true JP2020503351A5 (https=) | 2021-02-18 |
| JP7664020B2 JP7664020B2 (ja) | 2025-04-17 |
Family
ID=61193020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536179A Active JP7664020B2 (ja) | 2017-01-06 | 2018-01-05 | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
| JP2022180592A Active JP7682840B2 (ja) | 2017-01-06 | 2022-11-10 | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022180592A Active JP7682840B2 (ja) | 2017-01-06 | 2022-11-10 | カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11357841B2 (https=) |
| EP (1) | EP3565586B1 (https=) |
| JP (2) | JP7664020B2 (https=) |
| CA (1) | CA3049165A1 (https=) |
| ES (1) | ES3055314T3 (https=) |
| WO (1) | WO2018129336A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| MX2019004707A (es) * | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| CA3049165A1 (en) * | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| EP3635097A1 (en) * | 2017-06-05 | 2020-04-15 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US20210130779A1 (en) | 2018-04-27 | 2021-05-06 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US20230039976A1 (en) * | 2018-11-05 | 2023-02-09 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
| TW202039831A (zh) * | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療 |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| CN109536444B (zh) * | 2018-12-11 | 2022-06-28 | 吉林省拓华生物科技有限公司 | 一种适用于恶性实体瘤肿瘤浸润t淋巴细胞的分离诱导方法 |
| KR20200092155A (ko) * | 2019-01-24 | 2020-08-03 | 울산대학교 산학협력단 | 종양침윤림프구를 유효성분으로 포함하는 삼중음성 유방암 예방 또는 치료용 조성물 |
| GB201911066D0 (en) | 2019-08-02 | 2019-09-18 | Achilles Therapeutics Ltd | T cell therapy |
| WO2021123832A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| WO2021219990A1 (en) | 2020-04-28 | 2021-11-04 | Achilles Therapeutics Uk Limited | T cell therapy |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CA3196117A1 (en) * | 2020-10-22 | 2022-04-28 | Seth Wardell | Cell culture system and methods of using the same |
| TW202237824A (zh) * | 2020-11-23 | 2022-10-01 | 美商萊爾免疫藥物股份有限公司 | 培養免疫細胞之方法 |
| US20240123067A1 (en) * | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CA3207359A1 (en) * | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| EP4320435A1 (en) | 2021-04-09 | 2024-02-14 | Achilles Therapeutics UK Limited | Batch release assay for pharmaceutical products relating to t cell therapies |
| GB202109886D0 (en) | 2021-07-08 | 2021-08-25 | Achilles Therapeutics Uk Ltd | Assay |
| WO2022269250A1 (en) | 2021-06-22 | 2022-12-29 | Achilles Therapeutics Uk Limited | A method for producing antigen-specific t cells |
| WO2023077034A1 (en) * | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing immune cells |
| WO2023147505A2 (en) * | 2022-01-28 | 2023-08-03 | Cellular Biomedicine Group, Inc. | Method for enriching tumor infiltrating lymphocytes |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| AU7873187A (en) | 1986-08-08 | 1988-02-24 | University Of Minnesota | Method of culturing leukocytes |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US7479269B2 (en) | 1988-11-23 | 2009-01-20 | Genetics Institute, Llc | Methods for selectively enriching TH1 and TH2 cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| DE4447484C2 (de) | 1994-04-08 | 1997-07-17 | Deutsches Krebsforsch | Mittel zur Hemmung von Apoptose |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE386809T1 (de) | 1996-08-02 | 2008-03-15 | Bristol Myers Squibb Co | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| EP1135123B1 (en) | 1998-12-04 | 2004-12-29 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| WO2002000223A1 (en) * | 2000-06-26 | 2002-01-03 | Novo Nordisk A/S | Use of potassium channel agonists for reducing fat food comsumption |
| ES2382636T3 (es) | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7211561B2 (en) | 2001-10-12 | 2007-05-01 | Cedars-Sinai Medical Center | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| CA2478011C (en) | 2002-03-01 | 2013-05-21 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| WO2004003142A2 (en) | 2002-06-28 | 2004-01-08 | Xcyte Therapies, Inc. | Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| DE60334141D1 (de) | 2002-10-15 | 2010-10-21 | Facet Biotech Corp | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| CN101120083B (zh) | 2003-10-08 | 2013-03-27 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| CA2552788C (en) | 2004-01-12 | 2013-09-24 | Applied Molecular Evolution, Inc. | Fc region variants |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1765860T3 (da) | 2004-05-19 | 2009-03-09 | Immunocore Ltd | Ny-ESO-T.cellereceptor med höj affinitet |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1966370B1 (en) | 2005-12-21 | 2013-02-20 | SentoClone International AB | Method for obtaining T-lymphocytes |
| US8007785B2 (en) | 2005-12-21 | 2011-08-30 | Sentoclone International Ab | Method for treating colon cancer with tumour-reactive T-lymphocytes |
| US8211424B2 (en) | 2005-12-21 | 2012-07-03 | Sentoclone International Ab | Method for treating malignant melanoma |
| US8206702B2 (en) | 2005-12-21 | 2012-06-26 | Sentoclone International Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
| EP1894940A1 (en) | 2006-08-28 | 2008-03-05 | Apogenix GmbH | TNF superfamily fusion proteins |
| US7951365B2 (en) | 2007-06-27 | 2011-05-31 | Deifiera Falun Ab | Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types |
| EP2176288B1 (en) | 2007-07-10 | 2015-11-04 | Apogenix GmbH | Tnf superfamily collectin fusion proteins |
| EP2540740B1 (en) | 2008-06-17 | 2014-09-10 | Apogenix GmbH | Multimeric TNF receptors |
| DK2604693T3 (en) | 2008-07-21 | 2016-05-30 | Apogenix Gmbh | Single-chain TNFSF molecules |
| WO2014085437A2 (en) | 2012-11-27 | 2014-06-05 | The Johns Hopkins University | Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity |
| US20150320798A1 (en) | 2012-11-27 | 2015-11-12 | The Johns Hopkins University | Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity |
| JP5844158B2 (ja) | 2009-01-09 | 2016-01-13 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングＡｐｏｇｅｎｉｘ ＧｍｂＨ | 三量体形成融合タンパク質 |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US8809050B2 (en) | 2009-12-08 | 2014-08-19 | Wilson Wolf Manufacturing | Methods of cell culture for adoptive cell therapy |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| US20130115617A1 (en) | 2009-12-08 | 2013-05-09 | John R. Wilson | Methods of cell culture for adoptive cell therapy |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP2697367B1 (en) | 2011-04-13 | 2018-12-19 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| AU2012324644B2 (en) | 2011-10-21 | 2014-08-28 | Cell Medica Limited | Device for the aseptic expansion of cells |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| US9689876B2 (en) * | 2012-05-02 | 2017-06-27 | New York University | Methods related to cancer treatment |
| SG11201407226WA (en) | 2012-05-18 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
| CN104411819B (zh) | 2012-06-11 | 2019-05-10 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| RU2671897C2 (ru) | 2013-03-01 | 2018-11-07 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток |
| EP3628322A1 (en) | 2013-03-01 | 2020-04-01 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer |
| CN118562610A (zh) | 2013-06-24 | 2024-08-30 | 威尔逊沃夫制造公司 | 用于透气性细胞培养过程的封闭系统装置和方法 |
| WO2015039100A1 (en) | 2013-09-16 | 2015-03-19 | The Trustees Of The University Of Pennsylvania | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection |
| EP3943092B1 (en) | 2014-02-24 | 2024-11-13 | Energesis Pharmaceuticals Inc. | Compositions for use in inducing differentiation of human brown adipocyte progenitors |
| JP2017511375A (ja) | 2014-03-20 | 2017-04-20 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 養子細胞療法のための腫瘍浸潤リンパ球 |
| WO2015157636A1 (en) | 2014-04-10 | 2015-10-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| US11173146B2 (en) | 2014-04-25 | 2021-11-16 | The Regents Of The University Of California | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use |
| AU2015273501B2 (en) | 2014-06-11 | 2021-01-21 | Polybiocept Gmbh | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy |
| US9687510B2 (en) | 2014-09-04 | 2017-06-27 | The Johns Hopkins University | Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions |
| AU2014407539B2 (en) | 2014-10-02 | 2020-10-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation |
| EP3034092A1 (en) | 2014-12-17 | 2016-06-22 | Université de Lausanne | Adoptive immunotherapy for treating cancer |
| US10544392B2 (en) | 2015-05-01 | 2020-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood |
| FR3038324B1 (fr) | 2015-06-30 | 2020-10-30 | Lab Francais Du Fractionnement | Procede de cryoconservation de cellules a visee therapeutique |
| FR3040396A1 (fr) | 2015-06-30 | 2017-03-03 | Chu Nantes | Procede de cryoconservation de lymphocytes infiltrant la tumeur |
| WO2017048614A1 (en) | 2015-09-15 | 2017-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| CN108463547A (zh) | 2015-10-28 | 2018-08-28 | 生命技术股份公司 | 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群 |
| KR20190037243A (ko) | 2016-06-28 | 2019-04-05 | 지니우스 바이오테크놀로지 인코포레이티드 | 면역치료를 위한 티 세포 조성물 |
| CN106244538A (zh) | 2016-08-04 | 2016-12-21 | 英普乐孚生物技术(上海)有限公司 | 一种恶性腹水来源的til细胞的分离培养方法 |
| MX2019004707A (es) | 2016-10-26 | 2019-08-12 | Iovance Biotherapeutics Inc | Reestimulacion de linfocitos infiltrantes de tumor crioconservados. |
| WO2018102761A1 (en) | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| CN106591232A (zh) | 2017-01-04 | 2017-04-26 | 安徽安龙基因医学检验所有限公司 | 一种高效的pd‑1‑cd8+t细胞的培养方法 |
| CA3049165A1 (en) * | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| SG11201908271WA (en) | 2017-03-14 | 2019-10-30 | Juno Therapeutics Inc | Methods for cryogenic storage |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| CN107384867B (zh) | 2017-08-04 | 2020-09-11 | 北京世纪劲得生物技术有限公司 | 一种肿瘤组织til细胞制备方法及专用培养基 |
-
2018
- 2018-01-05 CA CA3049165A patent/CA3049165A1/en active Pending
- 2018-01-05 ES ES18704639T patent/ES3055314T3/es active Active
- 2018-01-05 JP JP2019536179A patent/JP7664020B2/ja active Active
- 2018-01-05 US US16/475,925 patent/US11357841B2/en active Active
- 2018-01-05 EP EP18704639.6A patent/EP3565586B1/en active Active
- 2018-01-05 WO PCT/US2018/012610 patent/WO2018129336A1/en not_active Ceased
-
2022
- 2022-06-10 US US17/838,127 patent/US20230210966A1/en active Pending
- 2022-11-10 JP JP2022180592A patent/JP7682840B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503351A5 (https=) | ||
| JP7462606B2 (ja) | ３－（５－アミノ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びＩｋａｒｏｓファミリージンクフィンガー２（ＩＫＺＦ２）依存性疾患の治療におけるその使用 | |
| Plautz et al. | Systemic T cell adoptive immunotherapy of malignant gliomas | |
| JP7483732B2 (ja) | ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 | |
| JP7488826B2 (ja) | 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 | |
| JP2020515257A5 (https=) | ||
| TWI253934B (en) | Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant | |
| JP2017507950A5 (https=) | ||
| JP2019534308A5 (https=) | ||
| CN114144182A (zh) | 使用2-(2,6-二氧代哌啶-3-基-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异二氢吲哚-1,3-二酮治疗非霍奇金淋巴瘤的方法 | |
| WO2016204193A1 (ja) | 抗がん剤 | |
| WO2021207828A1 (en) | Methods for treating cytokine release syndrome | |
| TWI858843B (zh) | 哌類化合物和ｐｄ－１抑制劑或ｐｄ－ｌ１抑制劑的組合物以及其在製備抗腫瘤藥物中的用途 | |
| JP2021535128A5 (https=) | ||
| EP3581182A2 (en) | Combination treating prostate cancer, pharmaceutical composition and treatment method | |
| JP2013526582A (ja) | 癌治療 | |
| US20210379106A1 (en) | Oxabicycloheptanes for enhancing car t cell function | |
| JPWO2021061870A5 (https=) | ||
| JP2025528115A (ja) | 腫瘍治療のための、放射線治療と組み合わせたピペラジン化合物の使用 | |
| EP3440196A1 (en) | Method for preparing lymphocytes capable of infiltrating a solid tumor, lymphocytes obtainable by said method and uses thereof | |
| WO2021154976A1 (en) | Methods of treating brain cancer with panobinostat | |
| CN111225672B (zh) | 甲羟戊酸通路抑制剂及其药物组合物 | |
| Chang et al. | Immunotherapy with sensitized lymphocytes | |
| CN120078889A (zh) | 用于治疗胰腺癌的药物组合物 | |
| JPWO2022132652A5 (https=) |